Journal article
Is there a role for peptide receptor radionuclide therapy in medullary thyroid cancer?
Clinical nuclear medicine, Vol.40(2), pp.123-127
02/2015
DOI: 10.1097/RLU.0000000000000628
PMID: 25546220
Abstract
Background
Medullary thyroid cancer (MTC) is a rare but potentially life-threatening disease with limited therapeutic options. As a neuroendocrine tumor, MTC expresses somatostatin receptors, and therefore, somatostatin-labeled radiopharmaceuticals could be used to treat patients with MTC.
Objective
The aims of this study were to evaluate tumor shrinkage after 177Lu-DOTATATE treatment, to analyze the impact on quality of life as accessed by the SF-36 questionnaire, and to demonstrate a possible prognostic role for 111In-DTPA-octreotide uptake in patients with MTC.
Patients and Methods
Patients with progressive MTC underwent evaluation using 111In-DTPA-octreotide. Patients who demonstrated 111In-DTPA-octreotide uptake were treated with 4 cycles of 200 mCi of 177Lu-DOTATATE and were evaluated using CT scans over 8 to 12 months of treatment.
Results
Of the 16 patients initially enrolled, 9 (56.25%) had lesions that were observed in the 111In-DTPA-octreotide scans and were eligible for therapy with 177Lu-DOTATATE. Three patients had a partial response, 3 patients were classified as having stable disease and, 1 patient had a progressive disease. All responders indicated improvement in quality of life 6 to 12 months after therapy.
Conclusions
Treatment with 177Lu-DOTATATE seems to be an alternative therapy for somatostatin receptor–positive tumors, with very mild adverse effects and quality-of-life improvement, at least during a short-term period. Further studies are needed to determine long-term benefits and to identify which patients are more likely to respond to this modality of therapy.
Details
- Title: Subtitle
- Is there a role for peptide receptor radionuclide therapy in medullary thyroid cancer?
- Creators
- Fernanda Vaisman - Instituto Nacional del CáncerPaulo Henrique Rosado De Castro - NuclearMedicine Service, Instituto Nacional de Câncer, Rio de Janeiro, BrazilFlavia Paiva Proença Lobo Lopes - NuclearMedicine Service, Instituto Nacional de Câncer, Rio de Janeiro, BrazilDaniel Barretto Kendler - Universidade Federal do Rio de JaneiroCencita H.N. Pessoa - Instituto Nacional del CáncerDaniel Alves Bulzico - Instituto Nacional del CáncerDouglas De Carvalho Leal - Radiology Service, Instituto Nacional de Câncer, Rio de Janeiro, BrazilBruno Vilhena - Oncology Service, Instituto Nacional de Câncer, Rio de Janeiro, BrazilMario Vaisman - Universidade Federal do Rio de JaneiroMichel Carneiro - NuclearMedicine Service, Instituto Nacional de Câncer, Rio de Janeiro, BrazilRossana Corbo - Instituto Nacional del Cáncer
- Resource Type
- Journal article
- Publication Details
- Clinical nuclear medicine, Vol.40(2), pp.123-127
- DOI
- 10.1097/RLU.0000000000000628
- PMID
- 25546220
- NLM abbreviation
- Clin Nucl Med
- ISSN
- 0363-9762
- eISSN
- 1536-0229
- Publisher
- Lippincott
- Number of pages
- 5
- Language
- English
- Date published
- 02/2015
- Academic Unit
- Radiology
- Record Identifier
- 9985143550702771
Metrics
1 Record Views